# Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

> **NCT00671034** · PHASE3 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 166 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Adult B Acute Lymphoblastic Leukemia
- Childhood B Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Calaspargase Pegol-mknl
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin Hydrochloride
- **DRUG:** Dexamethasone
- **DRUG:** Doxorubicin Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Mercaptopurine
- **DRUG:** Methotrexate
- **DRUG:** Pegaspargase
- **OTHER:** Pharmacological Study
- **DRUG:** Prednisone
- **RADIATION:** Radiation Therapy
- **DRUG:** Thioguanine
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT00671034
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07-21
- **Primary completion:** 2011-02-01
- **Final completion:** 2021-03-31
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2021-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00671034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00671034, "Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00671034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*